Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001193125-17-227592
Filing Date
2017-07-13
Accepted
2017-07-13 16:16:56
Documents
15

Document Format Files

Seq Description Document Type Size
1 424B3 d390888d424b3.htm 424B3 4555240
2 GRAPHIC g390888g05q44.jpg GRAPHIC 49368
3 GRAPHIC g390888g17g01.jpg GRAPHIC 47713
4 GRAPHIC g390888g19h08.jpg GRAPHIC 137147
5 GRAPHIC g390888g33d29.jpg GRAPHIC 91890
6 GRAPHIC g390888g36y62.jpg GRAPHIC 86635
7 GRAPHIC g390888g47h91.jpg GRAPHIC 49273
8 GRAPHIC g390888g49t77.jpg GRAPHIC 96082
9 GRAPHIC g390888g58h69.jpg GRAPHIC 35702
10 GRAPHIC g390888g59z64.jpg GRAPHIC 42231
11 GRAPHIC g390888g67m86.jpg GRAPHIC 58174
12 GRAPHIC g390888g95q73.jpg GRAPHIC 45509
13 GRAPHIC g390888g96s00.jpg GRAPHIC 65579
14 GRAPHIC g390888g97w78.jpg GRAPHIC 172054
15 GRAPHIC g390888g99q44.jpg GRAPHIC 44662
  Complete submission text file 0001193125-17-227592.txt   5965501
Mailing Address 2150 WOODWARD ST., SUITE 100 AUSTIN TX 78744
Business Address 3711 SOUTH MOPAC EXPRESSWAY, STE 100 AUSTIN TX 78746 512-901-0900
Mirna Therapeutics, Inc. (Filer) CIK: 0001527599 (see all company filings)

EIN.: 261824804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-218885 | Film No.: 17963751
SIC: 2834 Pharmaceutical Preparations